Pfizer Talks Up Phase III Pipeline To Offset Lipitor Pain
This article was originally published in Pharmaceutical Approvals Monthly
Pharma giant expects to have 24 to 28 programs in Phase III development by the end of 2009, representing a 50 percent to 70 percent increase, management says during an analyst day March 5. Pain and oncology are key disease areas Pfizer will focus on going forward. Investors, however, were unimpressed with the show
You may also be interested in...
Pfizer's CP-751,871 for metastatic non-small cell lung cancer recently became the first insulin-like growth factor 1 receptor inhibitor to enter Phase III trials, as the class gains popularity and strength
A regulatory filing for Vyjuvek in the US is targeted for the first half of 2022 following the positive results of a Phase III trial, positioning Krystal for its first commercial launch.
The company has ramped up a broad R&D program for the FcRn inhibitor in 11 autoantibody-driven disease areas.